BAYER AG NA O.N.
Commented by André Will-Laudien on February 4th, 2026 | 07:10 CET
Starting signal! Biotech sector benefits from rotation! Keep an eye on Evotec, Bayer, Vidac Pharma, and BioNTech
The stock market has started 2026 on a positive note. The mining and commodities sector recently proved that return opportunities are not limited to the technology sector, with several stocks doubling in price and a few even increasing tenfold. A breath of fresh air is needed, because other sectors also want to enjoy the stock market spring. Life science stocks have indeed taken a break for almost three years. But now they are back! After a long period of silence, selected companies are showing the first signs of a technical recovery. For investors with a penchant for opportunities and timing, now is the time to rethink old strategies and realign portfolios. In cancer research, recent breakthroughs in personalized immunotherapies have significantly increased the prospects of success for clinical trials. We take a closer look.
Read
Commented by Nico Popp on February 4th, 2026 | 07:05 CET
Solution to a billion-dollar problem: MustGrow Biologics validates business model – Revolutionary news also for Bayer and Corteva Agriscience
Canola is to Canada what oil is to Saudi Arabia: an economic driver of enormous proportions. With an estimated production value of around CAD 14 billion in 2025, the yellow-flowering crop is the "green gold" of the prairie. Yet this billion-dollar market is in danger: clubroot, an aggressive soil-borne disease, threatens crops and is already causing annual losses exceeding CAD 500 million. Previous solutions have reached their biological limits, but now the Canadian AgriTech company MustGrow Biologics is reporting a decisive success. As the company announced on Tuesday, its proprietary TerraMG™ technology has not only suppressed the disease in large-scale field trials, but also significantly increased yields. For agricultural giants like Bayer and Corteva, this could be the decisive lever to protect their high-performance seed varieties over the long term.
Read
Commented by André Will-Laudien on January 26th, 2026 | 07:30 CET
Biotech and life sciences are booming, and now Mercosur is joining the fray! Bayer, MustGrow, Novo Nordisk, and BioNxt Solutions in focus
The 2026 stock market year has a few surprises in store for investors. In addition to a quick resolution to the Greenland dispute, the Mercosur trade agreement with several South American countries is also moving forward. This agreement is particularly significant for the agricultural industry. This global sector of human supply is increasingly characterized by regulatory pressure, which is effectively ending the use of many synthetic pesticides and fertilizers. This development is forcing established agricultural companies to integrate effective biological alternatives into their portfolios faster than planned. In this environment, MustGrow Biologics is positioning itself as a strategic technology provider whose active ingredients have already been validated by leading market players. An expanded sector view also covers the life sciences industry with the protagonists Bayer, Novo Nordisk, and BioNxt. Up 50% in just a few weeks, here they are!
Read
Commented by Nico Popp on January 23rd, 2026 | 07:15 CET
Revolution in agricultural chemistry: How MustGrow Biologics is benefiting from the plight of Bayer and Corteva
Global agriculture is at a historic turning point, driven less by a belief in technological progress than by regulatory necessity. For decades, global food security has been based on synthetic pesticides and fertilizers, but that era is rapidly coming to an end. Authorities from Brussels to California are tightening the screws and banning established active ingredients one after the other because their ecological collateral damage is no longer tolerated. For the agricultural giants, this poses an existential threat: their full warehouses are in danger of becoming worthless if they do not find effective biological alternatives quickly enough. In the current extremely hectic environment in industry, which is characterized by billion-dollar acquisitions and strategic alliances, new power structures are emerging. While Corteva Agriscience is aggressively buying market share with its chequebook and Bayer is pushing ahead with its portfolio restructuring, the Canadian company MustGrow Biologics has carved out a position that is considered the "sweet spot" in the industry. The Company is the technology partner whose active ingredients have already been validated and licensed by the market leaders.
Read
Commented by André Will-Laudien on January 19th, 2026 | 07:20 CET
Black Monday: Despite Greenland disputes, tariffs, and Mercosur, biotech is on the rise! Bayer, Vidac Pharma, BioNTech, and Novo Nordisk in focus
The stock market has had a very volatile start to 2026. Now, due to the unresolved Greenland issue, punitive tariffs are even being reintroduced for European countries that wish to stick with the Danish administration. Questions of international law did not impact the stock market in any of the conflicts of 2025. What usually receives a lot of attention, however, are shrinking margins caused by artificial tariffs. Just as the EU had been patting itself on the back over the Mercosur agreement, the next Trump-style threat is looming. The biotech sector is advancing steadily and with considerable momentum. Can the life sciences leaders outperform the DAX?
Read
Commented by Fabian Lorenz on January 16th, 2026 | 07:05 CET
First Majestic reports, but the stock fails to benefit! Bayer continues to rise! Silver Viper takes off!
The upward trend in silver remains fully intact, and clear triple-digit price targets are circulating through the market. Yesterday, core holding First Majestic Silver reported on the fourth quarter and full year 2025. However, the stock failed to benefit from the news. Investors may find better opportunities in 2026 with Silver Viper shares. The silver explorer is undergoing a transformation and now holds three projects in Mexico. The most recent capital increase was met with strong demand, and drilling programs and results are expected in the current year. Looking at the share price chart of Bayer, one might think that the Leverkusen-based company had struck silver. The share price rose sharply in the first few days of the new year. However, analysts believe the upside potential has largely been exhausted.
Read
Commented by Nico Popp on January 14th, 2026 | 07:20 CET
Targeting cancer metabolism: Why Bayer and Pfizer are restructuring - and why Vidac Pharma is filling a scientific gap
The investment year 2026 marks a decisive turning point for the global biotechnology and pharmaceutical sector. After a period of macroeconomic uncertainty, we are witnessing a renaissance in the life sciences, driven by two fundamental forces: the urgent need for big pharma players to replace their expiring patents with innovation, and the scientific breakthrough of novel mechanisms of action in agile biotech small caps. While industry giants such as Pfizer and Bayer are attempting to steer their cumbersome tankers onto a new course through massive restructuring, the as-yet little-noticed biotech company Vidac Pharma is delivering the technological innovation the market is looking for. With an approach that directly addresses cancer metabolism and reverses the "Warburg effect," which has been known for almost a century, Vidac is positioning itself as a disruptive force in oncology and dermatology. For investors, this constellation offers a rare opportunity: to observe the stability of the giants while betting on the explosive potential of a technological innovator that analysts say is massively undervalued.
Read
Commented by André Will-Laudien on January 2nd, 2026 | 07:05 CET
Attention - fasten your seatbelts! 2026 could be a rocket launch for Novo Nordisk, Evotec, Bayer, and Vidac Pharma
The stock market is starting the new year 2026 in a buoyant mood. The mining and commodities sector showed that it is not only possible to make money with tech stocks, with almost every stock doubling in value, and some even increasing tenfold. The coming year, however, could bring yet another shift in perspective. The biotech sector has been quiet for quite some time, but some of the protagonists in our selection are showing, in part, significant technical base formations. For risk-aware investors, it may be time to reshuffle more decisively and realign portfolios. Come in and find out!
Read
Commented by Carsten Mainitz on December 23rd, 2025 | 08:45 CET
USD 600 billion market potential – Pfizer and Bayer are in the race, Vidac Pharma in the fast lane?
The market for cancer drugs is the largest segment within the pharmaceutical industry and currently has a volume of over USD 200 billion. According to experts, the market will already be worth USD 500 to 600 billion by 2032 or 2033. Companies such as Pfizer and Bayer are among the industry leaders. As is often the case, however, there are promising stocks from the second and third tiers beyond the blue chips. One such company is Vidac Pharma. The Company is pursuing a new, promising approach to skin cancer. Analysts attest to the shares' great potential.
Read
Commented by Armin Schulz on December 17th, 2025 | 07:05 CET
How Bayer, WashTec, and Volkswagen will earn more money in the future with digitalization and AI
Artificial intelligence is already generating measurable profits in industry today. In the pharmaceutical and chemical industries, it is revolutionizing research and accelerating the market launch of vital products. Mechanical and plant engineering is tapping into recurring sources of revenue with AI-based services and strengthening customer loyalty. And in the automotive industry, autonomous driving is highly popular and will shape the future. These advances prove that the productive phase of AI has begun. Three companies show how technology translates into competitive advantages and robust margins: Bayer, WashTec, and Volkswagen.
Read